India to Denmark Pharmaceutical Export

The pharmaceutical trade between India and Denmark has experienced significant growth over the past decade. In 2024, India exported pharmaceutical products valued at approximately $42.58 million to Denmark, marking a substantial increase from previous years. This upward trajectory reflects the strengthening of bilateral trade relations and India's growing presence in the European pharmaceutical market.

Key milestones in this evolution include the establishment of strategic partnerships between Indian pharmaceutical companies and Danish distributors, as well as the successful registration of Indian-made medicines with the Danish Medicines Agency. These developments have facilitated smoother market entry and enhanced the competitiveness of Indian pharmaceutical products in Denmark.

India holds a significant position in Denmark's pharmaceutical import landscape. In 2024, Denmark's pharmaceutical imports from India amounted to $26.89 million, indicating a robust demand for Indian pharmaceutical products. This positions India as a key supplier, contributing to Denmark's diverse pharmaceutical sourcing strategy.

Between 2024 and 2026, several developments have influenced the India-Denmark pharmaceutical trade. Notably, in July 2024, India and Denmark held bilateral trade discussions focusing on enhancing pharmaceutical exports, leading to streamlined regulatory processes and increased market access. Additionally, in March 2025, the Danish Medicines Agency updated its guidelines, facilitating the registration of foreign pharmaceutical products, which benefited Indian exporters.

Indian pharmaceutical companies seeking to register products in Denmark must adhere to the European Medicines Agency (EMA) guidelines. The Common Technical Document (CTD) format is mandatory for dossier submissions, ensuring consistency and compliance with European standards. A comprehensive bioequivalence study is required for generic products to demonstrate therapeutic equivalence to the reference medicine. The registration process typically spans 12 to 18 months, depending on the complexity of the product and the completeness of the submission.

Denmark mandates that manufacturing sites comply with Good Manufacturing Practice (GMP) standards as outlined by the EMA. Indian manufacturers must undergo inspections by the Danish Medicines Agency to verify adherence to these standards. The mutual recognition agreement between the EMA and the Indian regulatory authority, the Central Drugs Standard Control Organisation (CDSCO), facilitates this process, allowing inspections conducted by CDSCO to be recognized by the Danish authorities.

To import pharmaceutical products into Denmark, Indian exporters must provide several key documents:

• Certificate of Pharmaceutical Product (CPP): Issued by the CDSCO, confirming the product's market authorization in India.

• Certificate of Analysis (CoA): Demonstrates that the product meets quality standards.

• GMP Certificate: Indicates compliance with GMP standards.

These documents are essential for customs clearance and regulatory approval in Denmark.

The majority of India's pharmaceutical exports to Denmark consist of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. This aligns with Denmark's healthcare needs, which prioritize ready-to-use medications for its well-developed healthcare system. The therapeutic areas with the highest demand include antibiotics, antifungals, and cardiovascular drugs, reflecting the prevalence of related health conditions in Denmark.

The expiration of patents for several blockbuster drugs presents opportunities for Indian exporters to introduce generic versions to the Danish market. Additionally, the increasing demand for biosimilars in Europe offers a promising avenue for Indian pharmaceutical companies to expand their product portfolios. Exploring new therapeutic areas, such as oncology and immunology, could further enhance India's presence in Denmark's pharmaceutical sector.

Denmark's aging population and the rising incidence of chronic diseases drive the demand for pharmaceutical imports. The country's commitment to high-quality healthcare and its willingness to source medications globally contribute to the sustained demand for Indian pharmaceutical products. Furthermore, Denmark's robust healthcare spending ensures a steady market for imported medicines.

Denmark, as a member of the European Union, applies the EU's Most Favored Nation (MFN) tariff rates to pharmaceutical imports. These rates are generally low, facilitating the entry of foreign pharmaceutical products. Additionally, the EU's preferential trade agreements with various countries may offer duty exemptions or reductions, benefiting Indian exporters.

The EU has established free trade agreements (FTAs) with several countries, enhancing trade relations and reducing tariffs. While there is no specific FTA between India and Denmark, the EU-India FTA negotiations aim to improve trade ties, including the pharmaceutical sector. These agreements are expected to streamline regulatory processes and provide better market access for Indian pharmaceutical products in Denmark.

Denmark adheres to the European Union's intellectual property (IP) regulations, which include provisions for patent protection and data exclusivity. Indian generic manufacturers must navigate these IP laws, ensuring that their products do not infringe on existing patents. The EU's data exclusivity period, typically eight years, may delay the entry of generic versions of innovator drugs. However, the EU's compulsory licensing provisions allow for the production of generic medicines under certain conditions, providing a pathway for Indian exporters.

Pharmaceutical shipments from India to Denmark primarily utilize sea routes, with major ports such as Nhava Sheva (JNPT) and Chennai serving as key export points. The transit time for sea freight is approximately 25 to 30 days. Air freight, though more expensive, offers faster delivery, with transit times around 7 to 10 days. Recent geopolitical events, such as tensions in the Red Sea region, have not significantly disrupted these shipping routes.

In India, major export ports include Nhava Sheva (JNPT), Chennai, and Hyderabad ICD. In Denmark, key import ports are Copenhagen, Fredericia, and Kobenhavn. These ports are equipped to handle pharmaceutical shipments, ensuring efficient customs clearance and distribution within Denmark.

Maintaining the integrity of pharmaceutical products during transit is crucial. Temperature-controlled logistics are essential, especially for products requiring specific storage conditions. Compliance with Good Distribution Practice (GDP) standards ensures that products are stored and transported under appropriate conditions. Packaging must meet both Indian and EU regulations, providing adequate protection against environmental factors and physical damage.

Denmark's pharmaceutical market is valued at approximately $2.5 billion, with a steady growth rate of 3% annually. The market is characterized by a high demand for imported medicines, with generics accounting for about 40% of the total pharmaceutical consumption. This presents a substantial opportunity for Indian pharmaceutical exporters to expand their market share.

Denmark's healthcare system is publicly funded, providing universal coverage to its citizens. The government plays a significant role in drug procurement, often negotiating directly with suppliers to secure favorable pricing. Pharmaceutical companies must navigate these procurement processes, ensuring compliance with Denmark's healthcare policies and pricing regulations.

Indian pharmaceutical exporters have opportunities in Denmark's growing demand for generic medicines, especially in therapeutic areas such as oncology, cardiology, and immunology. The expiration of patents for several high-demand drugs opens avenues for introducing generic alternatives. Additionally, the EU's emphasis on biosimilars presents a promising market segment for Indian companies with the necessary capabilities.

Denmark sources pharmaceutical products from various countries, including China, other EU member states, and domestic producers. In 2024, Denmark imported pharmaceutical products worth $829.13 million, with China and EU countries being significant suppliers. India's share in this market is substantial but faces competition from these established suppliers.

India's competitive advantages include cost-effective manufacturing, adherence to WHO-GMP standards, and a broad portfolio of generic medicines. These factors enable Indian exporters to offer high-quality products at competitive prices, appealing to Denmark's cost-conscious healthcare system.

Key challenges for Indian pharmaceutical exporters include navigating complex EU regulations, ensuring compliance with stringent quality standards, and facing competition from low-cost producers like China. Additionally, maintaining a positive perception of product quality is crucial, as any lapses can impact market access and reputation.